Progress in Applicability of Scoring Systems Based on Nutritional and Inflammatory Parameters for Ovarian Cancer

Juan Mu, Yue Wu, Chen Jiang, Linjuan Cai, Dake Li, Jian Cao, Juan Mu, Yue Wu, Chen Jiang, Linjuan Cai, Dake Li, Jian Cao

Abstract

Ovarian cancer is a malignancy that seriously endangers women's health; its case fatality rate ranks first among the gynecological malignancies. The status of nutrition of ovarian cancer patients is related to their prognoses. Thus, it is important to evaluate, monitor, and improve the nutritional status of ovarian cancer patients during their treatment. Currently, there are several tools for examining malnutrition and nutritional assessment, including NRI (nutrition risk index), PG-SGA (patient-generated subjective global assessment), and NRS 2002 (nutritional risk screening 2002). In addition to malnutrition risk examination and related assessment tools, the evaluation of muscle mass, C-reactive protein, lymphocytes, and other inflammation status indicators, such as neutrophils to lymphocytes ratio, lymphocyte-to-monocyte ratio, and C-reactive protein-albumin ratio, is of great importance. The nutritional status of ovarian cancer patients undergoing surgery affects their postoperative complications and survival rates. Accurate evaluation of perioperative nutrition in ovarian cancer patients is crucial in clinical settings. An intelligent nutritional diagnosis can be developed based on the results of its systematic and comprehensive assessment, which would lay a foundation for the implementation of personalized and precise nutritional therapy.

Keywords: efficacy evaluation; inflammatory parameters; nutritional screening; nutritional support; ovarian cancer.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Mu, Wu, Jiang, Cai, Li and Cao.

References

    1. Xie W, Sun H, Li X, Lin F, Wang Z, Wang X. Ovarian cancer: epigenetics, drug resistance, and progression. Cancer Cell Int. (2021) 21:434. 10.1186/s12935-021-02136-y
    1. Wu Y, Mu J, Cao J, Li D, Dai Y. Research status and progress of nutritional support therapy for ovarian cancer. Nutr Cancer. (2021). [Epub ahead of print]. 10.1080/01635581.2021.1957132
    1. Rinninella E, Fagotti A, Cintoni M, Raoul P, Scaletta G, Quagliozzi L, et al. Nutritional interventions to improve clinical outcomes in ovarian cancer: a systematic review of randomized controlled trials. Nutrients. (2019) 11:1404. 10.3390/nu11061404
    1. Wattenberg MM, Beatty GL. Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle. Semin Cancer Biol. (2020) 65:38–50. 10.1016/j.semcancer.2020.01.002
    1. Hu C, Zhang Q, Shi H. Nutrition status of patients with common cancer in China: gap, mission and challenge. Sci China Life Sci. (2021) 64:1980–3. 10.1007/s11427-021-1954-4
    1. Veterans Affairs Total Parenteral Nutrition Cooperative Study Group. Perioperative total parenteral nutrition in surgical patients. N Engl J Med. (1991) 325:525–32. 10.1056/nejm199108223250801
    1. Oh CA, Kim DH, Oh SJ, Choi MG, Noh JH, Sohn TS, et al. Nutritional risk index as a predictor of postoperative wound complications after gastrectomy. World J Gastroenterol. (2012) 18:673–8. 10.3748/wjg.v18.i7.673
    1. Yim GW, Eoh KJ, Kim SW, Nam EJ, Kim YT. Malnutrition identified by the nutritional risk index and poor prognosis in advanced epithelial ovarian carcinoma. Nutr Cancer. (2016) 68:772–9. 10.1080/01635581.2016.1159702
    1. Yoon JW, Yim GW, Kim SW, Nam EJ, Kim S, Kim JW, et al. Nutritional Risk Index as a significant prognostic factor in advanced-stage epithelial ovarian cancer patients. Gynecol Oncol. (2014) 133:10. 10.1016/j.ygyno.2014.03.045
    1. Kondrup J, Rasmussen HH, Hamberg O, Stanga Z. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr. (2003) 22:321–36. 10.1016/s0261-5614(02)00214-5
    1. Bargetzi L, Brack C, Herrmann J, Bargetzi A, Hersberger L, Bargetzi M, et al. Nutritional support during the hospital stay reduces mortality in patients with different types of cancers: secondary analysis of a prospective randomized trial. Ann Oncol. (2021) 32:1025–33. 10.1016/j.annonc.2021.05.793
    1. Yang D, Zheng Z, Zhao Y, Zhang T, Liu Y, Xu X. Patient-generated subjective global assessment versus nutritional risk screening 2002 for gastric cancer in Chinese patients. Future Oncol. (2020) 16:4475–83. 10.2217/fon-2019-0539
    1. Cao J, Xu H, Li W, Guo Z, Lin Y, Shi Y, et al. Nutritional assessment and risk factors associated to malnutrition in patients with esophageal cancer. Curr Probl Cancer. (2021) 45:100638. 10.1016/j.currproblcancer.2020.100638
    1. Guo XW, Liu YC, Gao F, Ji SJ, Zhou JY, Ji L, et al. Pretreatment NRS-2002 scores combined with hematologic inflammation markers are independent prognostic factors in patients with resectable thoracic esophageal squamous cell carcinoma. Cancer Manage Res. (2018) 10:2409–18. 10.2147/cmar.S167179
    1. Hertlein L, Kirschenhofer A, Fürst S, Beer D, Göß C, Lenhard M, et al. Malnutrition and clinical outcome in gynecologic patients. Eur J Obstetr Gynecol Reprod Biol. (2014) 174:137–40. 10.1016/j.ejogrb.2013.12.028
    1. Hertlein L, Zeder-Göß C, Fürst S, Bayer D, Trillsch F, Czogalla B, et al. Peri-operative oral immunonutrition in malnourished ovarian cancer patients assessed by the nutritional risk screening. Arch Gynecol Obstetr. (2018) 297:1533–8. 10.1007/s00404-018-4759-8
    1. Kyle UG, Unger P, Mensi N, Genton L, Pichard C. Nutrition status in patients younger and older than 60 y at hospital admission: a controlled population study in 995 subjects. Nutrition. (2002) 18:463–9. 10.1016/s0899-9007(01)00804-8
    1. Kondrup J, Allison SP, Elia M, Vellas B, Plauth M. ESPEN guidelines for nutrition screening 2002. Clin Nutr. (2003) 22:415–21. 10.1016/s0261-5614(03)00098-0
    1. Cederholm T, Jensen GL. To create a consensus on malnutrition diagnostic criteria: a report from the Global leadership initiative on malnutrition (GLIM) meeting at the ESPEN Congress 2016. Clin Nutr. (2017) 36:7–10. 10.1016/j.clnu.2016.12.001
    1. Gupta D, Lis CG, Vashi PG, Lammersfeld CA. Impact of improved nutritional status on survival in ovarian cancer. Support Care Cancer. (2010) 18:373–81. 10.1007/s00520-009-0670-y
    1. Chantragawee C, Achariyapota V. Utilization of a scored patient-generated subjective global assessment in detecting a malnourished status in gynecologic cancer patients. Asian Pac J Cancer Prev. (2016) 17:4401–4.
    1. Phippen NT, Lowery WJ, Barnett JC, Hall LA, Landt C, Leath CA., III. Evaluation of the Patient-Generated Subjective Global Assessment (PG-SGA) as a predictor of febrile neutropenia in gynecologic cancer patients receiving combination chemotherapy: a pilot study. Gynecol Oncol. (2011) 123:360–4. 10.1016/j.ygyno.2011.07.093
    1. Das U, Patel S, Dave K, Bhansali R. Assessment of nutritional status of gynecological cancer cases in India and comparison of subjective and objective nutrition assessment parameters. South Asian J Cancer. (2014) 3:38–42. 10.4103/2278-330x.126518
    1. Laky B, Janda M, Cleghorn G, Obermair A. Comparison of different nutritional assessments and body-composition measurements in detecting malnutrition among gynecologic cancer patients. Am J Clin Nutr. (2008) 87:1678–85. 10.1093/ajcn/87.6.1678
    1. Poziomyck AK, Weston AC, Lameu EB, Cassol OS, Coelho LJ, Moreira LF. Preoperative nutritional assessment and prognosis in patients with foregut tumors. Nutr Cancer. (2012) 64:1174–81. 10.1080/01635581.2012.721157
    1. Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi. (1984) 85:1001–5.
    1. Matsumoto H, Okamoto Y, Kawai A, Ueno D, Kubota H, Murakami H, et al. Prognosis prediction for postoperative esophageal cancer patients using Onodera’s prognostic nutritional index. Nutr Cancer. (2017) 69:849–54. 10.1080/01635581.2017.1339093
    1. Yoshikawa N, Yoshida K, Tamauchi S, Ikeda Y, Nishino K, Niimi K, et al. The preoperative prognostic nutritional index for the prediction of outcomes in patients with early-stage ovarian clear cell carcinoma. Sci Rep. (2020) 10:7135. 10.1038/s41598-020-64171-5
    1. Komura N, Mabuchi S, Yokoi E, Shimura K, Kawano M, Matsumoto Y, et al. Prognostic significance of the pretreatment prognostic nutritional index in patients with epithelial ovarian cancer. Oncotarget. (2019) 10:3605–13. 10.18632/oncotarget.26914
    1. Komura N, Mabuchi S, Yokoi E, Shimura K, Kawano M, Matsumoto Y, et al. Pre-treatment prognostic nutritional index is superior to platelet count in predicting disease-specific survival in patients with epithelial ovarian cancer. Int J Gynecol Cancer. (2019) 29:1057–63. 10.1136/ijgc-2019-000492
    1. Feng Z, Wen H, Ju X, Bi R, Chen X, Yang W, et al. The preoperative prognostic nutritional index is a predictive and prognostic factor of high-grade serous ovarian cancer. BMC Cancer. (2018) 18:883. 10.1186/s12885-018-4732-8
    1. Miao Y, Li S, Yan Q, Li B, Feng Y. Prognostic significance of preoperative prognostic nutritional index in epithelial ovarian cancer patients treated with platinum-based chemotherapy. Oncol Res Treat. (2016) 39:712–9. 10.1159/000452263
    1. Zhang W, Ye B, Liang W, Ren Y. Preoperative prognostic nutritional index is a powerful predictor of prognosis in patients with stage III ovarian cancer. Sci Rep. (2017) 7:9548. 10.1038/s41598-017-10328-8
    1. Xiong SC, Hu X, Lia T, Wang YH, Li X. Prognostic significance of prognostic nutritional index in patients with renal cell carcinoma: a meta-analysis. Nutr Cancer. (2021). [Epub ahead of print]. 10.1080/01635581.2021.1931702
    1. Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr. (2017) 36:49–64. 10.1016/j.clnu.2016.09.004
    1. de Santana FM, Premaor MO, Tanigava NY, Pereira RMR. Low muscle mass in older adults and mortality: a systematic review and meta-analysis. Exp Gerontol. (2021) 152:111461. 10.1016/j.exger.2021.111461
    1. Chae SH, Lee C, Yoon SH, Shim SH, Lee SJ, Kim SN, et al. Sarcopenia as a predictor of prognosis in early stage ovarian cancer. J Korean Med Sci. (2021) 36:e2. 10.3346/jkms.2021.36.e2
    1. Staley SA, Tucker K, Newton M, Ertel M, Oldan J, Doherty I, et al. Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy. Gynecol Oncol. (2020) 156:695–700. 10.1016/j.ygyno.2020.01.003
    1. Kim SI, Kim TM, Lee M, Kim HS, Chung HH, Cho JY, et al. Impact of CT-determined sarcopenia and body composition on survival outcome in patients with advanced-stage high-grade serous ovarian carcinoma. Cancers. (2020) 12:559. 10.3390/cancers12030559
    1. Ataseven B, Luengo TG, du Bois A, Waltering KU, Traut A, Heitz F, et al. Skeletal muscle attenuation (sarcopenia) predicts reduced overall survival in patients with advanced epithelial ovarian cancer undergoing primary debulking surgery. Ann Surg Oncol. (2018) 25:3372–9. 10.1245/s10434-018-6683-3
    1. Rutten IJ, Ubachs J, Kruitwagen RF, van Dijk DP, Beets-Tan RG, Massuger LF, et al. The influence of sarcopenia on survival and surgical complications in ovarian cancer patients undergoing primary debulking surgery. Eur J Surg Oncol. (2017) 43:717–24. 10.1016/j.ejso.2016.12.016
    1. Yoshino Y, Taguchi A, Nakajima Y, Takao M, Kashiyama T, Furusawa A, et al. Extreme skeletal muscle loss during induction chemotherapy is an independent predictor of poor survival in advanced epithelial ovarian cancer patients. J Obstetr Gynaecol Res. (2020). [Epub ahead of print]. 10.1111/jog.14516
    1. Ubachs J, Koole SN, Lahaye M, Fabris C, Bruijs L, Schagen van Leeuwen J, et al. No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study. Gynecol Oncol. (2020) 159:706–11. 10.1016/j.ygyno.2020.09.042
    1. Huang CY, Yang YC, Chen TC, Chen JR, Chen YJ, Wu MH, et al. Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced-stage ovarian cancer. J Cachexia Sarcopenia Muscle. (2020) 11:534–46. 10.1002/jcsm.12524
    1. Aprile G, Basile D, Giaretta R, Schiavo G, La Verde N, Corradi E, et al. The clinical value of nutritional care before and during active cancer treatment. Nutrients. (2021) 13:1196. 10.3390/nu13041196
    1. Li S, Wang T, Tong G, Li X, You D, Cong M. Prognostic impact of sarcopenia on clinical outcomes in malignancies treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Oncol. (2021) 11:726257. 10.3389/fonc.2021.726257
    1. Bahat G, Turkmen BO, Aliyev S, Catikkas NM, Bakir B, Karan MA. Cut-off values of skeletal muscle index and psoas muscle index at L3 vertebra level by computerized tomography to assess low muscle mass. Clin Nutr. (2021) 40:4360–5. 10.1016/j.clnu.2021.01.010
    1. Yoshikawa T, Miyamoto M, Aoyama T, Matsuura H, Iwahashi H, Ishibashi H, et al. Psoas muscle index at the fifth lumbar vertebra as a predictor of survival in epithelial ovarian cancers. Mol Clin Oncol. (2021) 15:177. 10.3892/mco.2021.2339
    1. Matsubara Y, Nakamura K, Matsuoka H, Ogawa C, Masuyama H. Pre-treatment psoas major volume is a predictor of poor prognosis for patients with epithelial ovarian cancer. Mol Clin Oncol. (2019) 11:376–82. 10.3892/mco.2019.1912
    1. Yoshikawa T, Takano M, Miyamoto M, Yajima I, Shimizu Y, Aizawa Y, et al. Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers. Cancer Chemother Pharmacol. (2017) 80:555–61. 10.1007/s00280-017-3395-5
    1. Rutten IJG, Ubachs J, Kruitwagen R, Beets-Tan RGH, Olde Damink SWM, Van Gorp T. Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer. J Cachexia Sarcopenia Muscle. (2017) 8:630–8. 10.1002/jcsm.12180
    1. Aliustaoglu M, Bilici A, Gumus M, Colak AT, Baloglu G, Irmak R, et al. Preoperative serum leptin levels in patients with breast cancer. Med Oncol. (2010) 27:388–91. 10.1007/s12032-009-9222-z
    1. Minkov P, Gulubova M, Chilingirov P, Ananiev J. The position of neutrophils-to-lymphocytes and lymphocytes-to-platelets ratio as predictive markers of progression and prognosis in patients with non-small cell lung cancer. Open Access Maced J Med Sci. (2018) 6:1382–6. 10.3889/oamjms.2018.210
    1. Al Jarroudi O, El Bairi K, Abda N, Zaimi A, Jaouani L, Chibani H, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer. Biomark Med. (2021) 15:1289–98. 10.2217/bmm-2020-0717
    1. Medina Fernández FJ, Muñoz-Casares FC, Arjona-Sánchez A, Casado-Adam A, Gómez-Luque I, Garcilazo Arismendi DJ, et al. Postoperative time course and utility of inflammatory markers in patients with ovarian peritoneal carcinomatosis treated with neoadjuvant chemotherapy, cytoreductive surgery, and HIPEC. Ann Surg Oncol. (2015) 22:1332–40. 10.1245/s10434-014-4096-5
    1. Zhou M, Li L, Wang X, Wang C, Wang D. Neutrophil-to-lymphocyte ratio and platelet count predict long-term outcome of stage IIIC epithelial ovarian cancer. Cell Physiol Biochem. (2018) 46:178–86. 10.1159/000488420
    1. Feng Z, Wen H, Bi R, Ju X, Chen X, Yang W, et al. Preoperative Neutrophil-to-lymphocyte ratio as a predictive and prognostic factor for high-grade serous ovarian cancer. PLoS One. (2016) 11:e0156101. 10.1371/journal.pone.0156101
    1. Salman L, Sabah G, Jakobson-Setton A, Raban O, Yeoshoua E, Eitan R. Neutrophil-to-lymphocyte ratio as a prognostic factor in advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy. Int J Gynaecol Obstetr. (2020) 148:102–6. 10.1002/ijgo.12986
    1. Williams KA, Labidi-Galy SI, Terry KL, Vitonis AF, Welch WR, Goodman A, et al. Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. Gynecol Oncol. (2014) 132:542–50. 10.1016/j.ygyno.2014.01.026
    1. Sanna E, Tanca L, Cherchi C, Gramignano G, Oppi S, Chiai MG, et al. Decrease in neutrophil-to-lymphocyte ratio during neoadjuvant chemotherapy as a predictive and prognostic marker in advanced ovarian cancer. Diagnostics (Basel). (2021) 11:1298. 10.3390/diagnostics11071298
    1. Marchetti C, D’Indinosante M, Bottoni C, Di Ilio C, Di Berardino S, Costantini B, et al. NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer. Sci Rep. (2021) 11:11125. 10.1038/s41598-021-90361-w
    1. Wu YY, Qin YY, Qin JQ, Zhang X, Lin FQ. Diagnostic value of derived neutrophil-to-lymphocyte ratio in patients with ovarian cancer. J Clin Lab Anal. (2019) 33:e22833. 10.1002/jcla.22833
    1. Naina HV, Harris S. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. (2012) 366:1840. 10.1056/NEJMc1203095
    1. Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell. (2013) 24:130–7. 10.1016/j.ccr.2013.05.008
    1. Tuncer AA, Cavus S, Balcioglu A, Silay S, Demiralp I, Calkan E, et al. Can mean platelet volume, neutrophil-to-lymphocyte, lymphocyte-to-monocyte, platelet-to-lymphocyte ratios be favourable predictors for the differential diagnosis of appendicitis? J Pak Med Assoc. (2019) 69:647–54.
    1. Asher V, Lee J, Innamaa A, Bali A. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol. (2011) 13:499–503. 10.1007/s12094-011-0687-9
    1. Badora-Rybicka A, Nowara E, Starzyczny-Słota D. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer. ESMO Open. (2016) 1:e000039. 10.1136/esmoopen-2016-000039
    1. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol. (2012) 23:265–73. 10.3802/jgo.2012.23.4.265
    1. Zhang WW, Liu KJ, Hu GL, Liang WJ. Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients. Tumour Biol. (2015) 36:8831–7. 10.1007/s13277-015-3533-9
    1. Zhao Z, Zhao X, Lu J, Xue J, Liu P, Mao H. Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies. Arch Gynecol Obstetr. (2018) 297:849–57. 10.1007/s00404-018-4678-8
    1. Hamid HKS, Davis GN, Trejo-Avila M, Igwe PO, Garcia-Marín A. Prognostic and predictive value of neutrophil-to-lymphocyte ratio after curative rectal cancer resection: a systematic review and meta-analysis. Surg Oncol. (2021) 37:101556. 10.1016/j.suronc.2021.101556
    1. Wu M, Chen X, Lou J, Zhang S, Zhang X, Huang L, et al. Changes in regulatory T cells in patients with ovarian cancer undergoing surgery: preliminary results. Int Immunopharmacol. (2017) 47:244–50. 10.1016/j.intimp.2017.04.004
    1. Zhu Q, Wu X, Wu Y, Wang X. Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer. Oncol Rep. (2016) 36:3472–8. 10.3892/or.2016.5136
    1. Ou Y, Cannon MJ, Nakagawa M. Regulatory T cells in gynecologic cancer. MOJ Immunol. (2018) 6:34–42.
    1. Sousa LM, Almeida JS, Fortes-Andrade T, Santos-Rosa M, Freitas-Tavares P, Casanova JM, et al. Tumor and peripheral immune status in soft tissue sarcoma: implications for immunotherapy. Cancers. (2021) 13:3885.
    1. Yang HM, Lou G. The relationship of preoperativelymphocyte-monocyte ratio and the clinicopathological characteristics and prognosis of patients with epithelial ovarian cancer. Zhonghua Zhong Liu Za Zhi. (2017) 39:676–80. 10.3760/cma.j.issn.0253-3766.2017.09.007
    1. Kwon BS, Jeong DH, Byun JM, Lee TH, Choi KU, Song YJ, et al. Prognostic value of preoperative lymphocyte-monocyte ratio in patients with ovarian clear cell carcinoma. J Cancer. (2018) 9:1127–34. 10.7150/jca.24057
    1. Eo WK, Chang HJ, Kwon SH, Koh SB, Kim YO, Ji YI, et al. The lymphocyte-monocyte ratio predicts patient survival and aggressiveness of ovarian cancer. J Cancer. (2016) 7:289–96. 10.7150/jca.13432
    1. Gong J, Jiang H, Shu C, Hu MQ, Huang Y, Liu Q, et al. Prognostic value of lymphocyte-to-monocyte ratio in ovarian cancer: a meta-analysis. J Ovarian Res. (2019) 12:51. 10.1186/s13048-019-0527-z
    1. Kudou K, Saeki H, Nakashima Y, Kamori T, Kawazoe T, Haruta Y, et al. C-reactive protein/albumin ratio is a poor prognostic factor of esophagogastric junction and upper gastric cancer. J Gastroenterol Hepatol. (2019) 34:355–63. 10.1111/jgh.14442
    1. Ravindranathan D, Master VA, Bilen MA. Inflammatory markers in cancer immunotherapy. Biology (Basel). (2021) 10:325. 10.3390/biology10040325
    1. Li J, Jiao X, Yuan Z, Qiu H, Guo R. C-reactive protein and risk of ovarian cancer: a systematic review and meta-analysis. Medicine. (2017) 96:e7822. 10.1097/md.0000000000007822
    1. Toriola AT, Grankvist K, Agborsangaya CB, Lukanova A, Lehtinen M, Surcel HM. Changes in pre-diagnostic serum C-reactive protein concentrations and ovarian cancer risk: a longitudinal study. Ann Oncol. (2011) 22:1916–21. 10.1093/annonc/mdq694
    1. Komura N, Mabuchi S, Shimura K, Kawano M, Matsumoto Y, Kimura T. Significance of pretreatment C-reactive protein, albumin, and C-reactive protein to albumin ratio in predicting poor prognosis in epithelial ovarian cancer patients. Nutr Cancer. (2021) 73:1357–64.
    1. Liu Y, Chen S, Zheng C, Ding M, Zhang L, Wang L, et al. The prognostic value of the preoperative C-reactive protein/albumin ratio in ovarian cancer. BMC Cancer. (2017) 17:285. 10.1186/s12885-017-3220-x
    1. Sharma R, Hook J, Kumar M, Gabra H. Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer. Eur J Cancer. (2008) 44:251–6. 10.1016/j.ejca.2007.11.011
    1. Omichi C, Nakamura K, Haraga J, Masuyama H, Hiramatsu Y. Glasgow prognostic score is an independent marker for poor prognosis with all cases of epithelial ovarian cancer. Cancer Med. (2016) 5:1074–80. 10.1002/cam4.681
    1. Zhu J, Wang H, Liu CC, Lu Y, Tang H. The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. J Cancer Res Clin Oncol. (2016) 142:2339–45. 10.1007/s00432-016-2228-y
    1. Wang Y, Zheng J, Gao Z, Han X, Qiu F. Investigation on nutritional risk assessment and nutritional support status of surgical patients with colorectal cancer. J BUON. (2018) 23:62–7.
    1. Shen Y, Zhou Y, He T, Zhuang X. Effect of preoperative nutritional risk screening and enteral nutrition support in accelerated recovery after resection for esophageal cancer. Nutr Cancer. (2021) 73:596–601. 10.1080/01635581.2020.1764981
    1. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. (2010) 39:412–23. 10.1093/ageing/afq034

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa